Agios Pharm (AGIO)

Agios Pharm (AGIO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $2.2B; returns 1 day -0.5%, 1 week +18.1%, 1 year -12.1%.

Agios Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, with a near-term focus on hemolytic and acquired anemias. Its key product is AQVESME™ (mitapivat), a pyruvate kinase (PK) activator.

Groups AGIO belongs to

• Healthcare
• Biopharmaceutical
• Rare Diseases
• Biotechnology
• Commercial Stage Biotech
• Hematology
• Life Sciences
• Pharmaceuticals
• Sickle Cell Disease
• Metabolic Disorders

AGIO financial model: income statement, cash flow and balance sheet